They were randomly assigned to group I ( n = 35 ; intra-arterial infusion of rAd-p53 plus chemotherapy ) , group II ( n = 33 ; intra-arterial infusion of rAd-p53 plus placebo chemotherapy ) , or group III ( n = 31 ; intra-arterial infusion of placebo rAd-p53 plus chemotherapy ) .